Entera Bio Rebounds As Investors Balance Phase 3 Funding Against Dilution Risk
Entera Bio financing lifts ENTX as investors weigh a $275 million cash boost, EB613 funding and dilution risk.
Entera Bio got $275 million in new money to test and improve a medicine, which is exciting because it helps the company keep going. But the company had to give investors more ownership pieces, which means each piece gets a little smaller—so people are deciding if the money boost is worth that tradeoff.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.